Correlation of Biomarkers With the Presence and Severity of Coronary Artery Disease

This study includes three parts:

• Part 1 (Pilot analysis): 30 normal people and 30 patients with at least one epicardial coronary artery disease confirmed by angiography will be included. 10 ml peripheral blood from arterial sheath (just before angiography) will be collected in each subject. Proteomics analyses are performed in order to obtain the differentially expressed proteins (coded by Proteins 1-x.
• Part 2 (Training group): Differentially expressed Proteins 1-x are measured and compared between patients with diameter stenosis <70% (n=100) vs. with diameter stenosis ≥ 70%(n=100), respectively. Finally, Proteins 1-y from Proteins 1-x will be identified. Subgroups stratified by single-, double-, and triple-vessel disease will be performed.
• Part 3 (Validation group): The difference in blood concentration of Proteins 1-y between patients with different disease burden will be further analyzed: patients with diameter stenosis <70% (n=200) vs. diameter stenosis ≥70% (n=200), respectively. Subgroups stratified by single-, double-, and triple-vessel disease will be performed.

Inclusion criteria

• For Pilot study, both health and patients with at least one epicardial coronary artery disease are included
• For both Training group and Validation group, patients must have at least one epicardial coronary artery disease
• Left ventricular ejection fraction > 30%
• Stable or unstable angina
• Myocardial infarction older than 1 month
• No active inflammation
• No scheduled non-cardiac surgery within 12 months
• eGFR > 30 ml/min/m2
• Patients agree to participate in this study

Exclusion criteria

• Severe liver dysfunction
• Blood platelet count <100 x 109/L
• Cancer
• On dialysis
• Pulmonary hypertension (defined as mean pulmonary arterial pressure > 25 mmHg and pulmonary vessel resistance > 3.0 Woods Unit)